BIO-TECHNE ANNOUNCES COMPLETION OF CELL AND GENE THERAPY CATAPULT PROCESS ANALYTICAL TECHNOLOGY (PAT) CONSORTIUM

Rhea-AI Summary

Bio-Techne Corporation (NASDAQ: TECH) announced its completion of participation in the Cell and Gene Therapy Catapult Process Analytical Technology (Catapult PAT) consortium, a multi-year initiative involving 24 partners. The initiative, which began in January 2021, focused on developing cell and gene therapy-specific analytical technologies. Data was collected during experiments on T-cell expansion bioprocesses, resulting in a first-of-its-kind dataset. The Ella™ platform from Bio-Techne played a key role in the research, which is set to enhance facilities in the UK. Bio-Techne generated approximately $1.1 billion in net sales in fiscal 2022.

Positive

• Completion of the Catapult PAT consortium enhances Bio-Techne's reputation in cell and gene therapy.
• Ella™ platform demonstrated effectiveness, potentially increasing its adoption in clinical applications.

Negative

• None.

MINNEAPOLIS, March 15, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced it has completed its participation in the Cell and Gene Therapy Catapult Process Analytical Technology (Catapult PAT) consortium, a multi-year collaboration involving 24 partner companies, technology providers, therapy developers, and charities. The Catapult PAT consortium is the first initiative of this scale and functional expertise with member companies and organizations collaborating to develop cell and gene therapy-specific process analytical technologies.   

The PAT initiative began in January 2021 with a series of experiments designed to monitor process parameters of an exemplar 8-day T-cell expansion bioprocess using primary T-cells. Data were gathered from five independent analyses to generate an extensive, world-first dataset. An analysis of multiple cytokine targets was conducted using high-plex Luminex® immunoassays and the precision multiplexing Ella™ platform from Bio-Techne. The automated workflow of the Ella platform proved to be particularly amenable to the efficiency, accuracy, and throughput demands inherent in a bioprocess manufacturing environment. With its robust performance in this project, the Cell and Gene Therapy Catapult plans to incorporate Ella™ into an existing CGT Catapult facility to further support scientists in the UK.

"As a leader in the forefront of innovative tools to measure cytokines, we are honored to be a part of the Catapult PAT initiative to help advance cell and gene therapy development," said Will Geist, President of Bio-Techne's Protein Sciences Segment. "Bio-Techne remains excited about the potential of these advanced therapies to improve patient outcomes and treat a wide range of diseases that currently have very poor or ineffective treatments."  

Established by Innovate UK, the Cell and Gene Therapy Catapult fosters collaborations between academia, industry, and healthcare providers to develop new technology and drive innovation. Catapult experts cover all aspects of advanced therapies, from research and development to clinical adoption and every step in between.

About Bio-Techne
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-Techne generated approximately $1.1 billion in net sales in fiscal 2022 and has approximately 3,000employees worldwide. For more information on Bio-Techne and its brands, please visit http://www.bio-techne.com

About Bio-Techne Corporation (NASDAQ: TECH)
Contact: David Clair, Vice President, Investor Relations and Corporate Development
david.clair@bio-techne.com 
612-656-4416

View original content to download multimedia:https://www.prnewswire.com/news-releases/bio-techne-announces-completion-of-cell-and-gene-therapy-catapult-process-analytical-technology-pat-consortium-301772136.html

SOURCE Bio-Techne Corporation

FAQ

What is the significance of the Catapult PAT consortium for Bio-Techne (TECH)?

The consortium enhances Bio-Techne's role in advancing cell and gene therapy technologies.

When did Bio-Techne start participating in the Catapult PAT initiative?

Bio-Techne's participation began in January 2021.

What was the financial performance of Bio-Techne in fiscal 2022?

Bio-Techne generated approximately $1.1 billion in net sales in fiscal 2022.

Which platform did Bio-Techne utilize in the Catapult PAT consortium?

Bio-Techne utilized the Ella™ platform, known for its efficiency and accuracy in bioprocess environments.

How many companies were involved in the Catapult PAT consortium?

The consortium included 24 partner companies and organizations.